Letter From the Editor
Letter From the Editor: Addressing the Racial Gap in Health Care
Abstract: Over the past decade, the lung cancer landscape has been dominated by targeted and immunotherapeutic approaches that have drastically shifted treatment paradigms for patients with […]
Abstract: Over the past decade, the lung cancer landscape has been dominated by targeted and immunotherapeutic approaches that have drastically shifted treatment paradigms for patients with […]
Abstract: Low-grade serous carcinoma is a rare epithelial ovarian cancer subtype with distinct clinical, histologic, and molecular features. Improved understanding of this disease subtype has prompted […]
Abstract: Locally advanced gastrointestinal (GI) malignancies have conventionally been treated in a multimodal fashion that combines (neo)adjuvant chemotherapy with or without radiation and definitive surgical resection. […]
A Review of Selected Presentations From the ESMO Congress 2023 • October 20-24, 2023 • Madrid, Spain The Double Antibody Drug Conjugate (DAD) Phase I […]
A Review of Selected Presentations from SABCS 2022 • San Antonio, TX • December 6-10, 2022 EMERALD Phase 3 Trial of Elacestrant Versus Standard of Care […]
A Review of Selected Presentations from ASCO 2022, Chicago, IL, June 3-7, 2022; ESMO Breast Cancer Congress 2022, Berlin, Germany, May 3-5 2022; and ESMO Congress […]
Abstract: Kidney cancer is the eighth most commonly diagnosed cancer in the United States, and nearly one-third of patients have locally advanced or metastatic disease […]
Overview • Brain metastasis in patients with metastatic renal cell carcinoma generally signifies a poor prognosis. • Surgical resection is an option for patients with […]
Abstract: The non–clear cell renal cell carcinomas (nccRCCs) are a diverse group of rare-variant renal carcinomas. Each subtype harbors a distinct cell of origin and […]